fatnews.com Fatnews Bitchute Channel Link Home page  >  Article | Previous article | Next article



  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Symlin (pramlintide) (120 mcg three times per day) caused weight loss of 13.4 lbs in one year

    Posted by .(JavaScript must be enabled to view this email address)
    Thursday, September 11, 2008 11:49 am Email this article
    Symlin (pramlintide) at a dose of 120 mcg three times per day caused diabetics to lose an average of 7 pounds more than those given a placebo in four months which was 3.1 percent of body weight, and 13.4 pounds more than placebo after one year which was 5.6 percent of body weight according to a new study. Symlin (pramlintide) Approved for Diabetics on Insulin

    Symlin (pramlintide) approved in the U.S. for diabetics on insulin

    Symlin (pramlintide) is approved in the U.S. for use by type 1 and type 2 diabetics who use insulin.

    However, people in this study were not diabetic and not taking insulin.


    Symlin (pramlintide) Injected

    Symlin (pramlintide) is injected under the skin

    Pramlintide is a synthetic analog of amylin, a hormone that is released along with insulin in response to meals. It allows the use of less insulin.

    The drug is injected subcutaneously (under the skin).


    Dose Increased Gradually

    Dose increased 120 mcg every two weeks

    The starting dose was started at 120 mcg per day and then increased by 120 mcg per day every two weeks until the target dose was reached.


    Side Effects

    Side effects: Nausea in 9.3% of patients

    Mild to moderate nausea was the most common side effect reported by 9.3 percent of patients given the drug versus 2 percent of patients give the placebo.



    Subjects: 270 people

    The study was performed in 24 centers in the U.S. and started with 411 obese people (BMI of 30 or more) without diabetes who were 18- to 70-years-old.

    After four months there were 270 people still in the study.

    Approximately three-fourths of subjects were female.

    Subjects were randomized to received one of six drug treatments—120 mcg, 240 mcg or 360 mcg either two or three times per day—or a placebo.

    Out of these, 208 chose to continue the study for an additional eight months.


    Lifestyle Program Taught

    All patients taught lifestyle changes

    “All subjects participated in an individualized [lifestyle intervention] program based on LEARN” the paper notes.

    “LEARN is a commercially available program for weight management that encompasses diet, physical activity, and behavioral modifications and has been extensively used in pharmacological and nonpharmacological weight loss intervention studies.”

    Subjects were encouraged to reduce their calorie intake by 500 calories per day and to walk 10,000 steps per day.

    The subjects were also given a pedometer to measure steps.




    “When used over 12 months as an adjunct to [lifestyle intervention], pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss,” the researchers concluded.


    Smith S, Aronne L, Burns C, Kesty N, Halseth A, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008 Sep, 31(9):1816-23.


    Christian Weyer, MD
    Amylin Pharmaceuticals
    San Diego, California USA
    .(JavaScript must be enabled to view this email address)

    Steve R. Smith, MD
    Pennington Biomedical Research Center
    Louisiana State University
    Baton Rouge, Louisiana USA
    .(JavaScript must be enabled to view this email address)

    Articles on the same subject can be found here:


    Please feel free to share your comments about this article.




    Please enter the word you see in the image below:

    Remember my personal information

    Notify me of follow-up comments?

    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.